



Vaccines for Patients With Immunodeficiencies and Their Efficacy: An Overview in Pandemic Era

Guest Editors:

Prof. Dr. Lo Presti Elena

National Research Council (CNR)
—Institute for Biomedical
Research and Innovation (IRIB),
90146 Palermo, Italy

Dr. Trizzino Antonino

Department of Pediatric
Hematology and Oncology,
A.R.N.A.S. Civico Di Cristina and
Benfratelli Hospital, 90127
Palermo, Italy

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editors

Dear Colleagues, we are pleased to invite you to submit a contribution to this Special Issue

- The aim is to have a comprehensive analysis of types of vaccines in current use for Immunocompromised patients until the latest use for SARS-CoV2 infection. Taking in consideration the advanced technologies rapidly expanded over the last years in computational analysis or the predictive models and in vitro immunoassay, this special issue wants to explore the effectiveness of the vaccines to optimize the development of safety and tolerable protocols for vulnerable patients.
- This Special Issue will collect the following article types: Original research articles, Clinical Case reports, Reviews and Perspective analysis. The Research areas may include the following subjects (but not limited to): Clinical Immunology, Mathematical modeling, Machine learning analysis, Cellular Immunology. Allergology, Virology.

We look forward to receiving your contributions.

Prof. Dr. Lo Presti Elena

Dr. Trizzino Antonino

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)